Immunocore Presents Positive Monotherapy Data in Uveal Melanoma at the Society for Melanoma Research (SMR) 2016 Congress

9 November 2016 at 11:00 AM EST
  • IMCgp100 demonstrates clear early evidence of monotherapy activity in patients with uveal melanoma

  • Pivotal Phase II clinical study on track to be initiated in first quarter 2017

(Oxford, UK, 9th November 2016) Immunocore Limited, a world-leading biotechnology company developing novel T cell receptor (TCR) based biological drugs to treat cancer, infectious diseases and autoimmune diseases, will present positive data from its Phase I clinical monotherapy trial in uveal melanoma (UM) of its lead product, IMCgp100, an ImmTAC (Immune mobilising monoclonal TCRs Against Cancer). These data demonstrate clear early evidence of monotherapy activity of IMCgp100 in patients with uveal melanoma and strengthens the data announced at ASCO 2016.   

Alexander Shoushtari MD, PhD, Medical Oncologist at Memorial Sloan Kettering Cancer Center, will be giving an oral presentation at the Society for Melanoma Research (SMR) 2016 Congress at the Boston Marriott Copley Place Hotel in Boston, Massachusetts on 9th November, 2016 at 10.40am EST. The title of the presentation is: "A Phase I study of IMCgp100, a soluble HLA-A2 restricted gp100-specific T cell receptor-CD3 therapeutic with solid tumour activity in patients with advanced uveal melanoma".

In the study, 15 patients with UM were treated and are evaluable for efficacy.  Preliminary Phase I results suggest activity in UM.  Durable objective responses were observed and the disease control rate was 53% at 16 weeks and 40% at 24 weeks.  The study’s dosing regimen included an intra-patient escalation to mitigate the risk of cytokine release and IMCgp100 demonstrated a favourable safety profile with manageable T cell mediated toxicity. 

The Phase I study in UM will identify the escalated dose that can be administered in the intra-patient escalation regimen. The pivotal Phase II study in UM is on track to start dosing patients during the first quarter of 2017.

Dr Christina Coughlin, Chief Medical Officer at Immunocore, commented: “We continue to be encouraged by the clinical data we are observing with our lead asset, IMCgp100. Data from this trial so far has demonstrated clear early evidence of activity in uveal melanoma, an indication where patients have no treatments that have shown any survival benefit.  We look forward to taking this product further forward in its clinical development.”

Please click on the link below to download the full Press Release: